A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jun 2018

At a glance

  • Drugs AG 348 (Primary)
  • Indications Inborn error metabolic disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms ACTIVATE
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 18 Jun 2018 Status changed from not yet recruiting to recruiting, according to the Agios Pharmaceuticals media release.
    • 05 Jun 2018 Status changed from planning to not yet recruiting.
    • 08 Jan 2018 According to an Agios Pharmaceuticals media release, the company expects to initiate this trial in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top